MYL:NGS-Mylan N.V.

EQUITY | Drug Manufacturers | Nasdaq Global Select

Last Closing Price

USD 40.72

Change

0.00 (0.00)%

Market Cap

USD 20.96B

Volume

3.43M

Yahoo Analyst Target

USD 49.95 (22.67%)

STA Analyst Target

USD 47.71 (17.16%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Mylan NV along with its subsidiaries is a pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals.

Company Website : http://www.mylan.com

Currency: USD

Country : GBR

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-04-21 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
HCM Hutchison China MediTech Limit..

N/A

 USD 4.38B
GWPH GW Pharmaceuticals Plc

N/A

 USD 3.74B
IRWD Ironwood Pharmaceuticals Inc.

N/A

 USD 2.61B
SUPN Supernus Pharmaceuticals Inc.

N/A

 USD 2.50B
AKRX Akorn Inc.

N/A

 USD 2.47B
HZNP Horizon Pharma plc

N/A

 USD 2.26B
HRTX Heron Therapeutics Inc.

N/A

 USD 2.20B
MDCO The Medicines Company

N/A

 USD 2.16B
AERI Aerie Pharmaceuticals Inc.

N/A

 USD 2.12B
PAHC Phibro Animal Health Corporati..

N/A

 USD 1.77B

ETFs Containing MYL

GNRX VanEck Vectors Generic Dr.. 6.03 % 0.55 %

N/A

 USD 3.61M
XPH SPDR S&P Pharmaceuticals 4.17 % 0.35 %

N/A

 USD 0.35B
FTXH First Trust Nasdaq Pharma.. 4.10 % 0.60 %

N/A

 USD 3.21M
IHE iShares U.S. Pharmaceutic.. 3.66 % 0.44 %

N/A

 USD 0.38B
IBB iShares Nasdaq Biotechnol.. 3.03 % 0.47 %

N/A

 USD 8.67B
JKI iShares Morningstar Mid-C.. 1.17 % 0.30 %

N/A

 USD 0.42B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)		 Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.76% 43% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.76% 43% F 35% F
Trailing 12 Months  
Capital Gain 10.56% 60% D- 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.56% 60% D- 54% F
Trailing 5 Years  
Capital Gain 43.68% 62% D- 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.68% 62% D- 44% F
Average Annual (5 Year Horizon)  
Capital Gain 3.75% 44% F 41% F
Dividend Return 3.75% 44% F 36% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 29.02% 87% B+ 46% F
Risk Adjusted Return 12.91% 51% F 32% F
Market Capitalization 19.44B 100% A+ 97% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)		 Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 71.90 6% F 17% F
Price/Book Ratio 1.61 69% D+ 63% D
Price / Cash Flow Ratio 2.51 21% F 47% F
Price/Free Cash Flow Ratio 18.51 9% F 29% F
Management Effectiveness  
Return on Equity 5.45% 80% B- 55% F
Return on Invested Capital 5.34% 87% B+ 53% F
Return on Assets 1.97% 87% B+ 67% D+
Debt to Equity Ratio 117.00% 24% F 21% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

MYL:NGS-Mylan N.V.

EQUITY | Drug Manufacturers | Nasdaq Global Select

Last Closing Price

USD 40.72

Change

0.00 (0.00)%

Market Cap

USD 20.96B

Volume

3.43M

Yahoo Analyst Target

USD 49.95 (22.67%)

STA Analyst Target

USD 47.71 (17.16%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-04-21